Search research articles
Contact Us
Filters
Showing results (221-230 of 302) with videos related to
Page
of 31
Sort By:
The New England Journal of Medicine
|
May 16, 2019
Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice André, Eva Ciruelos, Gabor Rubovszky, et al.
Breast Cancer Research and Treatment
|
March 29, 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials
Elie Rassy, Thomas Filleron, Alessandro Viansone, et al.
NPJ Precision Oncology
|
June 3, 2026
When effective anticancer therapies are, in fact, destabilizing the tumor's Group Phenotypic Composition
Frédéric Thomas, Antoine M Dujon, Andriy Marusyk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P Goetz, Masakazu Toi, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
José Baselga, Vladimir Semiglazov, Peter van Dam, et al.
Oncotarget
|
February 28, 2016
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
Emeline Tabouret, François Bertucci, Jean-Yves Pierga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2021
Patient-Reported Outcomes in Patients With <i>PIK3CA</i>-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
Eva Maria Ciruelos, Hope S Rugo, Ingrid A Mayer, et al.
The Lancet. Oncology
|
February 16, 2019
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi, Anita Giobbie-Hurder, Andrea Gombos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 26, 2023
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Tobias Kessler, Daniel Schrimpf, Laura Doerner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 15, 2020
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Caroline Rousseau, David M Goldenberg, Mathilde Colombié, et al.
Page
of 31
Search research articles
Search
Showing results (221-230 of 302) with videos related to
Sort By:
Page
of 31
The New England Journal of Medicine
|
May 16, 2019
Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice André, Eva Ciruelos, Gabor Rubovszky, et al.
Breast Cancer Research and Treatment
|
March 29, 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials
Elie Rassy, Thomas Filleron, Alessandro Viansone, et al.
NPJ Precision Oncology
|
June 3, 2026
When effective anticancer therapies are, in fact, destabilizing the tumor's Group Phenotypic Composition
Frédéric Thomas, Antoine M Dujon, Andriy Marusyk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P Goetz, Masakazu Toi, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
José Baselga, Vladimir Semiglazov, Peter van Dam, et al.
Oncotarget
|
February 28, 2016
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
Emeline Tabouret, François Bertucci, Jean-Yves Pierga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2021
Patient-Reported Outcomes in Patients With <i>PIK3CA</i>-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
Eva Maria Ciruelos, Hope S Rugo, Ingrid A Mayer, et al.
The Lancet. Oncology
|
February 16, 2019
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi, Anita Giobbie-Hurder, Andrea Gombos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 26, 2023
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Tobias Kessler, Daniel Schrimpf, Laura Doerner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 15, 2020
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Caroline Rousseau, David M Goldenberg, Mathilde Colombié, et al.
Page
of 31